Business
Tempest Therapeutics, Inc.: BUSINESS Overview We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates.
Net income increased 37.2% to ($26.3M), while Operating cash flow increased 18.8% to ($26.8M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($26.3M)Watch
- Cash generation — Free cash flow ($26.8M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 1 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Leadership changes
From Tempest Therapeutics, Inc.'s own filings, the day they're filed.
- Justin Trojanowski · President · appointmenteff. 2026-06-05
- John David Yee · directors · appointmenteff. 2026-06-04
- Christine Pellizzari · Directors · departureeff. 2026-05-22
Latest filings
- 8-K · Company announcement2026-08-24
- 8-K · Company announcement2026-08-18
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Tempest Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.